Baraka Ahmad, Salem Hatem M
Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Egypt J Immunol. 2011;18(2):23-30.
Regulatory T cells (Tregs) play a central role in protecting the host from autoimmune diseases. However, Tregs also pose a major problem to anti-tumor immunity. The expansion and accumulation of these immunosuppressive cells correlate with advanced tumor growth and predict poor disease prognosis. The study aims at evaluation of the clinical role of regulatory T cells in B-cell Non-Hodgkin's lymphoma. The study was carried out on 45 de novo patients with B- NHL, they included 26 males and 19 females and 20 apparently healthy age-matched as control. Diagnosis of lymphoma was done by lymph node biopsy, 15 patients had diffuse large B cell lymphoma (DLBCL), 9 follicular lymphoma (FL), 8 small cell lymphocytic lymphoma (SCLL), 7 marginal zone lymphoma (MZL) and 6 had mantle cell lymphoma (MCL). Tregs (CD4+CD25+ FoxP+3) were analyzed by Flowcytometry. The mean percent was 10.9 +/- 1.6% in diffuse large B cell lymphoma, 12.4 +/- 1.4% in follicular lymphoma, 13.7 +/- 2.4% in small cell lymphocytic lymphoma, 11.9 +/- 1.9% in marginal zone lymphoma and 13.5 +/- 1.35% in mantle cell lymphoma as compared to 5.9 +/- 0.96% in controls with a significant increase in the patients in relation to control group. Tregs was significantly increased in advanced stages of the disease, in bone marrow infiltration and in patients with increased LDH level. In conclusion, Tregs may play a role in modifying immune responses in patients with lymphomas and may be useful in immunotherapy and new anti-lymphoma strategies involving depletion of Tregs.
调节性T细胞（Tregs）在保护宿主免受自身免疫性疾病侵害方面发挥着核心作用。然而，Tregs也给抗肿瘤免疫带来了一个主要问题。这些免疫抑制细胞的扩增和积累与肿瘤的晚期生长相关，并预示着疾病预后不良。本研究旨在评估调节性T细胞在B细胞非霍奇金淋巴瘤中的临床作用。该研究对45例初发B-NHL患者进行，其中包括26名男性和19名女性，另有20名年龄匹配的明显健康者作为对照。通过淋巴结活检诊断淋巴瘤，15例为弥漫性大B细胞淋巴瘤（DLBCL），9例为滤泡性淋巴瘤（FL），8例为小细胞淋巴细胞淋巴瘤（SCLL），7例为边缘区淋巴瘤（MZL），6例为套细胞淋巴瘤（MCL）。通过流式细胞术分析Tregs（CD4+CD25+FoxP+3）。弥漫性大B细胞淋巴瘤中Tregs的平均百分比为10.9±1.6%，滤泡性淋巴瘤中为12.4±1.4%，小细胞淋巴细胞淋巴瘤中为13.7±2.4%，边缘区淋巴瘤中为11.9±1.9%，套细胞淋巴瘤中为13.5±1.35%，而对照组为5.9±0.96%，患者组相对于对照组有显著增加。在疾病晚期、骨髓浸润以及乳酸脱氢酶水平升高的患者中，Tregs显著增加。总之，Tregs可能在淋巴瘤患者的免疫反应调节中发挥作用，并且可能在涉及Tregs耗竭的免疫治疗和新的抗淋巴瘤策略中有用。
